Post-traumatic Stress Disorder Treatment Market - Top Companies and Manufacturers

Companies Dominating the Post-traumatic Stress Disorder (PTSD) Treatment Landscape

The PTSD treatment market is extremely fragmented, with both small enterprises and large companies in competition. To treat PTSD symptoms, pharmaceutical firms are developing and marketing both new and well-known drugs, like anxiolytics and antidepressants. The market is competitive and dynamic, with a constant focus on improving patient outcomes and innovation.

Some of the prominent players include:

Jazz Pharmaceuticals plc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Bionomics Limited
Merck KGaA
Pfizer Inc.
Aurobindo Pharma Limited
GlaxoSmithKline plc (GSK plc)
Viatris Inc.
Jubilant Pharmova Ltd.
H. Lundbeck A/S
Camber Pharmaceuticals, Inc.

Browse Key Market Insights with Data Illustration:

Post-traumatic Stress Disorder (PTSD) Treatment Market Report 2037

In the News

In July 2024, Bionomics Limited, a biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, announced the start of patient screening for the Phase 3 AFFIRM-1 trial evaluating the safety and efficacy of BNC210 for the acute, as-needed treatment of social anxiety disorder (SAD).
In November 2021, Camber Pharmaceuticals announced the addition of Sertraline Hydrochloride Tablets to their current portfolio, which are the generic form of Zoloft. Sertraline Hydrochloride Tablets are prescribed to treat major depressive disorder, obsessive-compulsive disorder (OCD), panic disorder, social anxiety disorder (SAD), and post-traumatic stress disorder (PTSD).

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of PTSD treatment was over USD 17.7 billion.

The market size for post-traumatic stress disorder (PTSD) treatment is projected to cross USD 35.1 billion by the end of 2037 expanding at a CAGR of 5.4% during the forecast period i.e., between 2025-2037.

The major players in the market are Jazz Pharmaceuticals plc, Bionomics Limited, Merck KGaA, Pfizer Inc., Aurobindo Pharma Limited, GlaxoSmithKline plc (GSK plc), Viatris Inc., Jubilant Pharmova Ltd., H. Lundbeck A/S, Camber Pharmaceuticals, Inc., and others.

The adult segment is anticipated to garner a share/size of 84.7% % during 2025-2037.

The North America post-traumatic stress disorder (PTSD) treatment sector is poised to hold a 40.7% share by the end of 2037.

Post-traumatic Stress Disorder Treatment Market - Top Companies and Manufacturers

Companies Dominating the Post-traumatic Stress Disorder (PTSD) Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the post-traumatic stress disorder (PTSD) treatment industry?

What is the outlook for the PTSD treatment market?

Who are the major players dominating the post-traumatic stress disorder treatment landscape?

Which segment will capture the significant market share for post-traumatic stress disorder (PTSD) treatment by 2037?

Which region will provide more opportunities for the post-traumatic stress disorder (PTSD) treatment business in 2037?